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Abstract
Microglial activation is a characteristic feature of the pathogenesis of prion diseases. The molecular mechanisms that
underlie prion-induced microglial activation are not very well understood. In the present study, we investigated the role of
the class B scavenger receptor CD36 in microglial activation induced by neurotoxic prion protein (PrP) fragment 106–126
(PrP106–126). We first examined the time course of CD36 mRNA expression upon exposure to PrP106–126 in BV2 microglia. We
then analyzed different parameters of microglial activation in PrP106–126-treated cells in the presence or not of anti-CD36
monoclonal antibody (mAb). The cells were first incubated for 1 h with CD36 monoclonal antibody to block the CD36
receptor, and were then treated with neurotoxic prion peptides PrP106–126. The results showed that PrP106–126 treatment led
to a rapid yet transitory increase in the mRNA expression of CD36, upregulated mRNA and protein levels of proinflammatory
cytokines (IL-1b, IL-6 and TNF-a), increased iNOS expression and nitric oxide (NO) production, stimulated the activation of
NF-kB and caspase-1, and elevated Fyn activity. The blockade of CD36 had no effect on PrP106–126-stimulated NF-kB
activation and TNF-a protein release, abrogated the PrP106–126-induced iNOS stimulation, downregulated IL-1b and IL-6
expression at both mRNA and protein levels as well as TNF-a mRNA expression, decreased NO production and Fyn
phosphorylation, reduced caspase-1 cleavage induced by moderate PrP106–126 –treatment, but had no effect on caspase-1
activation after treatment with a high concentration of PrP106–126. Together, these results suggest that CD36 is involved in
PrP106–126-induced microglial activation and that the participation of CD36 in the interaction between PrP106–126 and
microglia may be mediated by Src tyrosine kinases. Our findings provide new insights into the mechanisms underlying the
activation of microglia by neurotoxic prion peptides and open perspectives for new therapeutic strategies for prion diseases
by modulation of CD36 signaling.
Citation: Kouadir M, Yang L, Tan R, Shi F, Lu Y, et al. (2012) CD36 Participates in PrP106–126-Induced Activation of Microglia. PLoS ONE 7(1): e30756. doi:10.1371/
journal.pone.0030756
Editor: Joseph El Khoury, Massachusetts General Hospital and Harvard Medical School, United States of America
Received February 24, 2011; Accepted December 22, 2011; Published January 26, 2012
Copyright:  2012 Kouadir et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: 1 Ministry of Agriculture, Key Program, China (Project No. 2009ZX08008-010B and No. 2009ZX08007-008B). 2 Ministry of Agriculture Key Program,
China (Project No. 2009ZX08007-008B). 3 The Natural Science Foundation of China (Project No. 31001048, No. 30972164, and No. 30871854). 4 Beijing Natural
Science Foundation (Project No. 6101002). 5 The Program for Cheung Kong Scholars and Innovative Research Team in University of China (No. IRT0866). The
funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: zhaodm@cau.edu.cn
. These authors contributed equally to this work.
Introduction
Prion diseases are a group of transmissible fatal neurodegener-
ative disorders of humans and animals, including bovine
spongiform encephalopathy (BSE) in cattle, scrapie in sheep, and
Creutzfeldt-Jakob disease (CJD) in humans. They are caused by
the conversion of cellular prion protein (PrP
C) into the
pathological isoform (PrP
Sc) through conformational changes
[1,2]. Neuropathological features of prion diseases include
neuronal vacuolation, neuronal loss, astrogliosis and accumulation
of activated microglial cells in affected brain areas [3].
Microglia, the resident macrophages of the central nervous
system parenchyma, are exquisitely sensitive to pathological tissue
alterations, altering their morphology and phenotype to adopt a
so-called activated state and perform immunological functions in
response to pathophysiological brain insults [4,5]. A wealth of data
now demonstrate that the microglia have very diverse effector
functions, in line with macrophage populations in other organs
[6]. Mounting evidences also indicate that microglial activation
contributes to neuronal damage in several neurodegenerative
diseases including Alzheimer’s disease, prion diseases, Parkinson’s
disease, multiple sclerosis, and Huntington’s disease [5,7]. In prion
diseases and other neurodegenerative disorders, microglia can
become overactivated and release ROS, NO, and cytokines, which
might cause vascular damage in addition to neurodegeneration
[7,8,9,10]. Pattern recognition receptors expressed on the
microglial surface, including Toll-like receptors and scavenger
receptors seem to associate physically to form a receptor complex,
which is one of the primary, common pathways through which
diverse toxin signals are transduced into ROS production in
microglia [4,11].
Scavenger receptor CD36 is a cell surface protein that is
differentially regulated in microglia through development and in
response to disease,and is known to be involved in microglia-
mediated immune response in the central nervous system [12,13].
The role of CD36 in the amyloid-beta (Ab)-induced microglial
PLoS ONE | www.plosone.org 1 January 2012 | Volume 7 | Issue 1 | e30756activation in Alzheimer’s disease has been extensively investigated
[11,14], but there has been no report so far of its role in prion
diseases.
Neurotoxic prion protein (PrP) fragment 106–126 (PrP106–126)
possesses similar physicochemical and pathological properties to
PrP
Sc, in that it forms amyloid fibrils with high b-sheet content,
shows partial proteinase K resistance, and is neurotoxic in vitro
[15]. Therefore, PrP106–126 is commonly used as a model for the
investigation of PrP
Sc neurotoxicity.
In the present study, we investigated the role of the class B
scavenger receptor CD36 in the activation of murine microglia
induced by PrP106–126. The results of this study suggest that CD36
participates in PrP106–126-induced microglial activation by medi-
ating iNOS, and pro-inflammatory cytokines up-regulation
through the activation of Src tyrosine kinases.
Materials and Methods
Isolation and culture of microglia cells
Primary microglial cell cultures were obtained from neonatal
Wistar rats 5–7 days old, according to the method described by
Garcao et al. [9]. After sterilization with 75% ethanol for 3–5 min,
the brain was dissected and the meninges were carefully removed
under a stereomicroscope. Cerebral cortexes were collected and
the tissue was dissociated by pipetting up and down for
approximately 10 times, and then digested with trypsin (0.125%)
for 15–20 min at 37uC, which was terminated with DMEM
containing serum. The digested tissue was repeatedly pipetted to
obtain the maximum number of single cells [16]. Then the cells
were passed through a 200 mm mesh to obtain a single-cell
suspension. After centrifugation at 100 g for 5 min and the cellular
pellet was resuspended in DMEM containing 10% FCS, penicillin
and streptomycin, and then plated in a 35 mm plastic tissue
culture flask [17]. The mixed glia cells were cultured for about 6–7
days. The cells were suspended by agitation for 12 h on a rotary
shaker (180 rpm) at 37uC and transferred to another flask. After
incubation for 2 h at 37uC, microglia that selectively adhered to
the plastic flask were washed with Ca2+/Mg2+-free PBS and
grown in a serum-free medium before treatment with PrP106–126
(see below). The purity of the microglia cells was approximately
90% determined using anti-CD-11b antibodies.
BV2 cells, a murine microglia cell line, were obtained from
Xiehe Medical University (Beijing, China).Cells were maintained
in a 95% air, 5% CO 2 atmosphere in DMEM-F12 supplemented
with 10% fetal bovine serum (FBS; GIBCO), 100 mg/mL
streptomycin, 100 U/mL penicillin (GIBCO), and 2 mM gluta-
mine permilliliter.
Prion peptides. PrP peptides PrP106–126 and scrambled
PrP106–126 (Scr-PrP) with sequence of KTNMKHMAGAAA-
Table 1. Primers used for real-time PCR and cloning.
Genes Primer sequences (59-39) PCR product size Annealing temperature Genbank accession no.
b-actin TGCTGTCCCTGTATGCCTCTG 223 bp 60uC NM_007393
TTGATGTACCGCACGATTTCC
CD36 TCGGAACTGTGGGCTCATTG 294 bp 65uC NM_001159555.1
CCTCGGGGTCCTGAGTTATAT TTT C
IL-1b GCCTCAAAGGAAAGAATCTA 297 bp 47uC NM_008361
AAACAGTCCAGCCCATACTT
IL6 TGCCTTCTTGGGACTGAT 384 55uC NM_031168
CTGGCTTTGTCTTTCTTGTT
TNF-a GGCGGTGCCTATGTCTCA 221 bp 55uC NM_013693
CACTTGGTGGTTTGCTACG
doi:10.1371/journal.pone.0030756.t001
Figure 1. Quantitative RT-PCR analysis of PrP106–126 effect on
mRNA expression of CD36. A. Electrophoresis of RT-PCR-amplified
CD36 (294 bp) and b-actin (223 bp) on 8% agarose gel and stained with
ethidium bromide. B. Time course of CD36 mRNA Expression upon
exposure to PrP106–126 in BV2 microglia. Cells were treated for 3, 6, 12 h,
or 24 hours with 100 mM PrP106–126. Total mRNA was isolated and
reverse-transcribed. The mRNA level of CD36 were measured by
quantitative RT-PCR. Expression of a receptor at each time point is
expressed as a percentage of expression in control cells exposed to
100 mM scrambled PrP106–126 only for the same time. All data are mean
6 s.d. of triplicate samples and are representative of an experimental n
of 3 or 4. *, P,0.05.
doi:10.1371/journal.pone.0030756.g001
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synthesized by Sangon Bio-Tech. The peptides were dissolved in
Phosphate Buffer Solution (PBS) at a concentration of 2 mM and
stored at 220uC as the stock solutions. The purity of prion
peptides was .95% according to the synthesizer’s data. The
peptide solution (500 mM) in PBS (pH 7.4) was aged for 2–3 days
at 37uC before use to increase fibrillogenicity of the peptide [16].
Reagents. The rabbit anti-mouse NF-kB p65, CD36, NOS-2
(i-NOS), caspase1, and p-Fyn antibodies were acquired from
Beyotime Biotechnology (China), Gene Tex (Texas, USA),
Hantian Biotechnology (China), Wuhan Boster Biotech (Wuhan,
China), and Bioworld Technology (USA), respectively. Anti-mouse
b-actin, and Max antibody were purchased from Beyotime
Biotechnology (China). ELISA kits for mouse interleukins and
Fast Protein Precipitation and Concentration KIT were purchased
from Wuhan Boster Biotech (Wuhan, China). Reagents and
apparatus used in immunoblotting assays were obtained from Bio-
Rad (Hercules, CA). Alkaline phosphatase-linked anti-rabbit
secondary antibody was from Beyotime Biotechnology (China).
Peptide treatment. Prion peptide 106–126 was aggregated
for 72 h at 37uC in DMEM-F12 medium. Microglia were exposed
or not to 1 mg/ml anti-CD36 antibody for 1 h and then treated
with the aggregated peptide PrP106–126 in culture medium. Scr-
PrP was used as a negative control. Three wells were used in each
group of experimental conditions.
Extraction of nuclear and cytoplasmic protein and
Western blotting. After cells treatment with 50 mMo r
100 mM PrP106–126 for 12 or 24 h, the culture medium was
discarded and cytoplasmic and nuclei proteins were extracted using
Extract kit (Beyotime Biotechnology Inc., China). Equal amounts of
protein were separated by SDS-PAGE on 8% gels, and the
separated proteins were transferred onto a nitrocellulose
membrane. Nonspecific binding sites were blocked by incubating
the membrane with 5% fat-free dried milk in TBST (10 Mm
TrisHC1, pH 7.5, 0.15 M NaCl, 0.05% Tween20) or bovine serum
albumin (during the assessment of p-Fyn levels). Rabbit anti NF-kB
p65 (1:500), anti-iNOS (1:200), anti-caspase1 (1:100), or anti-p-Fyn
(1:500) antibodies were added and incubated for 1 h at 4uC.
Membranes were washed with TBST and then incubated with the
secondary antibody, an anti-rabbit horseradish peroxidase-
conjugated goat antiserum (1:5000). Bands of immuno-reactive
protein were visualized, after membrane incubation with ECF
Figure 2. The mRNA expression of proinflammatory cytokines IL-1b, IL-6, and TNF-a, in BV2 microglia treated with PrP106–126 in the
presence or not of anti-CD36 antibody. Cells were first pre-incubated or not with Anti-CD36 antibody (1 mg/ml) or irrelevant rabbit IgG (Ab) and
then treated for 12 hours with 50 mM PrP106–126 (PrP). Total mRNA was isolated and reverse-transcribed. The mRNA levels of pro-inflammatory
cytokines were measured by quantitative RT-PCR. The mRNA level of each cytokine is expressed as fold increase over control cells which were
exposed to PBS only. Data are means 6 s.d. of triplicate samples *P, 0.05.
doi:10.1371/journal.pone.0030756.g002
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stripped and reprobed with antiactin antibody (for cytoplasmic
extracts) or anti-Max (for nuclear extracts) to estimate the total
amount of protein loaded in gel.
Cytokine Release Assessment. The levels of interleukin-1b
(IL-1b), IL-6, TNF-a and i-NOS were determined in culture
supernatants of BV2 microglia cells (0.2610
6 cells/cm2) treated
for 12 h with the peptides(50 mM), anti-CD36 mAb (1 mg/ml),
or combination of both of them by using enzyme-linked
immunosorbent assay (ELISA) kits specific for mouse IL-1b,I L -
6, TNF-a and i-NOS. The samples of culture supernatants,
controls, and standards were first treated by Fast Protein
Precipitation and Concentration KIT (Wuhan Boster Biotech,
China) to increase protein concentration before ELISA analysis.
Samples were then pipetted into microplates of these ELISA kits,
according to the manufacturer’s instructions (R&D Systems). The
experiments were performed in duplicate, in four to six
independent cell preparations. The absorbance was measured at
450 nm, with the correction wavelength at 540 nm, using
microplate reader. The values were read off the standard curve
and expressed as nanograms per liter (IL-1b, IL-6, TNF-a)o rU /
L(i-NOS).
Nitrite assay. Nitric oxide (NO) production was determined
by the nitrite (NO22) assay with the Griess reagent (0.1% N-(1-
naphtyl)ethylenediamine dihydrochloride, 1% sulphanilamide and
2% phosphoric acid).The assay is based on the measurement of
NO22, a stable endproduct of the reaction between NO and
molecular oxygen. Primary microglia were first pre-incubated or
not with Anti-CD36mAb (1 mg/ml) or irrelevant rabbit IgG (Ab)
and then treated for 12 hours with PBS, 50 mM PrP106–126 (PrP),
or scrambled PrP106–126. Culture supernatants (50 ml) were
mixed with an equal volume of Griess reagent for 15 min in the
dark at room temperature, according to the method described by
Huygen [18]. Absorbance was measured at 550 nm with a
microplate reader. The nitrite concentration was determined from
a sodium nitrite standard curve ranging from 0 to 100 mM. All
experiments were performed in duplicate, in four to six
independent cell preparations.
Real-time quantitative RT-PCR analysis of the expression
of CD36 and proinflammatory cytokines. To determine the
mRNA expression of CD36 and proinflammatory cytokines, real-
time PCR was carried out. Endogenous house-keeping gene b-
actin was used as cDNA template control. PCR primers were used
for amplification of genes cloned for real-time PCR (see Table 1).
For construction of a standard curve, amplified fragments of target
genes were cloned into pGEM-T-Vector by T-A clone technique,
and five 10-fold serial dilutions of plasmid DNA ranging from 10
2
to 10
6 molecules were then prepared. Real-time quantitative PCR
was performed using a DNA Engine Opticon
TM 2 system (MJ
Research, USA) and DyNAmo
TM SYBR@ Green quantitative
PCR kit (MJ Research, Waltham, MA, USA). The primers were
used to amplify cDNA of the biological sample, negative controls
and five plasmid DNA standards. PCR reaction system was
carried out in a real-time PCR tube. The total volume was 20 ml,
Figure 3. Proinflammatory cytokines (IL-1b, IL-6, and TNF-a) produced by BV2 cells treated with PrP106–126 in the presence or not of
anti-CD36 antibody. Cells were first pre-incubated or not with Anti-CD36 antibody (1 mg/ml), and then treated for 12 h with PBS or PrP106–126
(50 mM). The level of released cytokines was determined in culture supernatants by ELISA as described in Materials and methods. The amount of
cytokines (A: IL-1b, B: IL-6 and C: TNF-a) is expressed as ng/l cell supernatant. All data are means 6 s.d. of triplicate samples and are representative of
an experimental n of 3 or 4, * P,0.05.
doi:10.1371/journal.pone.0030756.g003
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10 ml Master Mix and 25 ng of reverse transcribed total RNA or
plasmid DNA of the respective concentration. The PCR
amplification was as follows: after denaturation at 94uCf o r
5 min, 36 PCR cycles were performed including 94uC for 30 s,
62uC for 20 s, 72uC for 20 s, and 1 s at 84uCa p p e n d e df o ra
single fluorescence measurement above melting temperature of
possible primer-dimers. Finally a melting step was performed
consisting of 10 s at 65uC and slow heating with a rate of 0.1uC
per second up to 95uC with continuous fluorescence measure-
ment. The mRNA levels of CD36 and proinflammatory cytokines
were calculated using an absolute standard curve method [19,20].
The cDNA samples were amplified in parallel with plasmid
standards in each run and their Ct values were plotted together
with the standard curves, from which the normalized mRNA
copy numbers were determined. All samples were analyzed in
triplicate.
Statistical analysis. Differences between groups were
assessed by one-way ANOVA and post hoc Turkey’s test
using SPSS 13.0 software (USA). Data are expressed as means
6 S.D. Differences with P,0.05 were considered statistically
significant.
Results
1- PrP106–126 induced an increase of CD36 mRNA levels in
BV2 microglia
BV2 cells were incubated with 100 mM of neurotoxic PrP106–126
or Scr-PrP for 3, 6, 12, and 24 h. RNA aliquots extracted from
treated BV2 cells were reverse transcribed as described in Materials
and Methods, and the PCR was used to amplify cDNA specific for
b-actin, and CD36 (Fig. 1-A). Fig. 1-B shows time course of CD36
mRNA expression upon exposure to PrP106–126 in BV2 microglia
and is expressed as a percentage of CD36 expression in control cells
exposed to 100 mMS c r - P r Po n l y .
The mRNA level of CD36 in PrP106–126-treated cells was
highest at 6 h, when it was 1-fold higher compared to the level in
ScrPrP-treated control cells. After 6 h, the mRNA level in
PrP106–126-treated cells steadily decreased up to 24 h, but it
was still slightly higher than the level in the control (Fig. 1-B).
Figure 4. Role of CD36 in PrP106–126-induced production of nitric oxide and iNOS expression in BV2 and primary microglia. Cells
were first pre-incubated or not with anti-CD36mAb (1 mg/ml) or irrelevant rabbit IgG (Ab) and then treated for 12 hours with PBS, 50 mM PrP106–126
(PrP), or scrambled PrP106–126 (Scr). A. The level of NO was measured in supernatant from primary microglia culture with nitrite assay as described in
Materials and Methods. The amount of nitric oxide is expressed as U/l cell supernatant. B. ELISA was performed on supernatant from culture of BV2
microglia as described in Materials and methods. All data in A and B are means 6 s.d. of triplicate samples and are representative of an experimental
n of 3 or 4, * P,0.05. C. Cytoplasmic extracts from primary microglia were prepared and immunoblotted with anti-iNOS antibody as described in
Materials and Methods. The blot was stripped and reprobed with anti-b-actin antibody to estimate the total amount of protein loaded in gel.
Representative blots of iNOS and actin are shown. Bars represent the relative levels of iNOS, compared with b-actin, and were expressed as arbitrary
units. Data are the means6S.D of three independent experiments. * P,0.05, significantly different from control cells. 1-PBS, 2–50 mM PrP106–126,3 -
PrP106–126+irrelevant rabbit IgG (Ab), 4- Prpscr (50 mM), 5- Anti-CD36mAb (1 mg/ml), 6- PrP106–126+Anti-CD36mAb.
doi:10.1371/journal.pone.0030756.g004
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inflammatory cytokines mRNA expression, and IL-1b and
IL-6 protein level in microglia
The treatment of BV2 cells for 12 h with PrP106–126 led to a
significant increase in IL-1b,I L - 6a n dT N F - a at both mRNA and
protein levels. For the three cytokines, the increase was statistically
significant compared with the level in the cells treated with PBS where
the level of cytokines did not significantly change (Fig. 2 and 3).
CD36 blockade with anti-CD36 monoclonal antibody resulted
in a significant decrease of the mRNA level of the three cytokines
in PrP106–126-treated cells. This blocking effect was specific as
almost no change was observed on PrP106–126-stimulating effect on
the mRNA level of the three cytokines in cells pre-incubated with
irrelevant rabbit IgG before PrP106–126 treatment (Fig. 2).
Pretreatment of BV2 cells with anti-CD36 monoclonal antibody
downregulated the PrP106–126-induced release of IL-1b and IL-6 as
shown by ELISA. The downregulation induced by CD36
blockade was statistically significant for IL6 but not for IL-1b
(Fig. 3.A and B). The level of TNF-a released slightly increased
after CD36 blockade but was not significantly higher than the level
released after PrP106–126 treatment (Fig. 3.C). The treatment with
anti-CD36 monoclonal antibody alone did not induce any change
in the levels of the three cytokines.
Treatment of BV2 cells with Scr-PrP (negative control) or LPS
(positive control) led to no change or a significant increase,
respectively, in the mRNA and the protein levels of the three
cytokines (Data not shown).
3- PrP106–126 induced a CD36-dependent upregulation of
iNOS and NO production
The level of NO in primary microglia treated with 50 mM
PrP106–126 (2.1960.09 mM / m ls u p e r n a t a n t )f o r1 2h rw a sh i g h e r
than, but not significantly different (P.0.05) from that observed
in control cells treated with 50 mMS c r - P r P( 1 . 5 4 60.12 mM/ml
supernatant). CD36 blockade with anti-CD36 monoclonal
antibody prior to PrP106–126 treatment significantly decreased
(P,0.05) NO level (1.1960.32 mM/ml supernatant). This
blocking effect was specific as pretreatment with irrelevant
rabbit IgG did not affect PrP106–126-induced increase in NO level
(Fig. 4-A).
To determine whether the alterations in NO production caused
by neurotoxic PrP peptides and CD36 blockade was correlated
with alterations in iNOS expression, we examined the level of
iNOS in the protein extract from primary microglia and
supernatant from BV2 culture exposed to PrP106–126 in the
presence or not of anti-CD36 antibody.
Figure 5. Western blot analysis of p65 nuclear translocation. BV2 microglia were treated or not with two different concentrations of
neurotoxic prion peptides (50 mM and 100 mM, respectively) for 24 h. The role of CD36 in NF-KB activation was examined by 1 h-preincubation with
anti-CD36 antibody. A. Extracts were prepared and immunoblotted with p65 antibody as described in Materials and Methods. The blot was stripped
and reprobed with anti-Max antibody to estimate the total amount of nuclear protein loaded in gel. Representative blots of p65 and Max are shown.
B. Bars represent the relative levels of p65, compared with Max, and were expressed as arbitrary units. Data are the means6S.D of three independent
experiments. * P,0.05, significantly different from control cells.
doi:10.1371/journal.pone.0030756.g005
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the up-regulation of iNOS in BV2 and primary microglia as
shown by ELISA and Western blot analysis (Fig. 4-B and C). Pre-
treatment with anti-CD36 antibody followed by PrP106–126
stimulation significantly inhibited the PrP106–126-induced iNOS
up-regulation (Fig. 4-B and C). No iNOS activation was observed
in primary microglia treated with anti-CD36 monoclonal antibody
or Scr-PrP alone (Fig. 4-C). Again, the blocking effect of anti-
CD36 antibody was specific as pretreatment with irrelevant rabbit
IgG did not affect PrP106–126-induced increase in iNOS level
(Fig. 4-C). Treatment of BV2 cells with LPS (positive control) led
to a significant increase in the level of iNOS (Data not shown). The
level of i-NOS was significantly higher in cells treated with PrP106–
126 or irrelevant rabbit IgG plus PrP106–126 than in all other
examined groups (p,0.05).
4- The Blockade of CD36 did not affect PrP106–126-induced
NF-kB
The Treatment of BV2 cells with 50 mM or 100 mM PrP106–126
led to the activation of NF-kB as indicated by the presence of NF-
kB p65 in the nuclear protein extract of the treated cells (Fig. 5).
The nuclear translocation of p65 was not affected by CD36
blockade with anti-CD36 antibody (Fig. 5). Even a ten-fold
increase of the concentration of anti-CD36 antibody (from 1 mg/
ml to 10 mg/ml) to block CD36 did not inhibit PrP106–126-induced
NF-kB activation (Data not shown). No p65 nuclear translocation
was observed in the cells treated with Scr-PrP, PBS, or CD36
monoclonal antibody alone (Fig. 5).
5- PrP106–126 induced caspase-1 activation even after the
Blockade of CD36
Immunoblot analysis of caspase-1 showed that PrP106–126
induced the cleavage of caspase-1 to its active p10 subunit both
at 50 mM and 100 mM concentrations (Fig. 6).
Pretreatment with anti-CD36 mAb slightly reduced PrP106–126-
induced activation of caspase-1 in BV2 cells treated with 50 mM
PrP106–126, but had no effect on caspase-1 cleavage after tratement
with a higher concentration (100 mM) of PrP106–126 (Fig. 6).
Capase-1 cleavage was not observed in BV2 cells treated with
ScrPrP106–126, PBS, or CD36 monoclonal antibody alone (Fig. 6).
Treatment with 10 mM Amyloid beta, which was used as a positive
control, also led to Capase-1 cleavage.
Figure 6. Western blot analysis of caspase-1 cleavage. BV2 microglia were treated or not with two different concentrations of neurotoxic prion
peptides (50 mM and 100 mM, respectively) for 24 h. The role of CD36 in caspase1 cleavage was examined by 1 h-preincubation with anti-CD36
antibody. A. Extracts were prepared and immunoblotted with caspase-1 antibody as described in Materials and Methods. The blot was stripped and
reprobed with anti-b-actin antibody to estimate the total amount of protein loaded in gel. Representative blots of caspase-1 and b-actin are shown.
Extracts of Ab1–42-treated cells were used as positive control. B. Bars represent the relative levels of cleaved caspase-1, compared with b-actin, and
were expressed as arbitrary units. Data are the means6S.D of three independent experiments. * P,0.05, significantly different from control cells.
doi:10.1371/journal.pone.0030756.g006
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Fyn activity
Immunoblot analysis of phospho-Fyn (p-Fyn) showed that
treatment with 100 mM PrP106–126 led to Fyn activation as
indicated by the increase in the level of p-Fyn. The level of p-Fyn
was higher in cells treated with PrP106–126 than in those treated
with PBS. Blockade of CD36 with anti-CD36 monoclonal
antibody significantly reduced PrP106–126-induced increase in the
level of p-Fyn (Fig. 7).
Discussion
Microglia activation involves multiple pathways that result in
morphological changes, proliferation and release of bioactive
substances that play an important role in the onset and progression
of neurodegenerative diseases such as Alzheimer’s disease and
prion diseases [5]. Several studies have reported that PrP synthetic
peptides induce microglial activation [21,22,23,24]. The identifi-
cation of cell surface molecules that mediate the PrP synthetic
peptides interaction with microglia is of great importance as it
represents the first point of intervention in the events leading to the
pathophysiology of prion diseases. Our approach to investigate the
role of CD36 in the PrP106–126-induced microglia activation
derived from consideration of its well-documented role in other
protein misfolding-diseases such as Alzheimer’s disease.
We started by examining the effect of exposure to PrP106–126
(100 mM) on the expression of CD36 gene in BV2 cells. The
mRNA level of CD36 increased significantly after 6 h of exposure
to the prion peptides and steadily decreased during the time
interval between 12 and 24 h. The general pattern of the
expression of CD36 mRNA observed in this experiment is similar
to that that we have reported in a recent study [25]. In that study,
the concentration of PrP106–126 was lower (50 mM) and the
increase in CD36 started earlier (at 3 h) but started to decrease at
6 h. Our result is consistent with many reports in the literature
supporting the idea of inducible overexpression of CD36 in
microglia after exposure to amyloid fibril [26,27], and is
compatible with a possible participation of CD36 in PrP106–126-
induced microglial activation.
Our approach then consisted of examining the effect of blocking
CD36 by monoclonal antibody on several parameters of microglial
activation. The adoption of this approach was motivated by the
fact that CD36 tends to act as a component of a cell surface
receptor complex that mediates the binding of microglia to fibrillar
proteins or other ligands [11,28,29]. We hypothesized that by
blocking CD36 with its monoclonal antibody we could compet-
itively inhibit the formation of the receptor complex and this
would reveal its role in the process of microglial activation upon
stimulation with prion peptides.
Proinflammatory cytokines are important effector molecules
that act as proinflammatory factors and are thought to paly an
important role in neurodegeneration. There have been conflicting
reports of the effect of prion peptides on the level of inflammatory
cytokines in microglia [23,30,31]. In this study, we showed that
PrP106–126 induced a significant increase in the expression of IL-
1b, IL-6 and TNF-a both at mRNA and protein levels.
Interestingly, pretreatment with anti-CD36 monoclonal antibody
significantly abrogated the PrP106–126-induced increase in the
mRNA expression of the three cytokines. At the protein level,
however, the blocking effect of anti-CD36 antibody was
maintained only for IL-6, IL-1b, albeit not significantly for the
latter. In contrast, CD36 blockade did not alter PrP106–126-induced
increase in the protein level of TNF-a although it significantly
downregulated the increase in its mRNA transcription induced by
PrP106–126 treatment. These results suggest that CD36 blockade
did not downregulate TNF-a mRNA transcription to the extent
that would affect its protein synthesis and support a central role of
CD36 in the signaling that leads to the up-regulation of IL-6, IL-
1b in microglia upon exposure to PrP106–126.
It is well established that stressful conditions can trigger the
expression of iNOS, which can generate NO from Larginine
[32]. In this study, we reported that PrP106–126 induced an
increase in iNOS level and NO secretion in primary microglia.
This is in line with other reports that almost invariably reported
the upregulation of iNOS and release of NO in macrophages and
microglia exposed to neurotoxic prion peptides [9,30,31].
Moreover, we showed that CD36 blockade significantly abrogat-
ed the effect of PrP106–126 treatment on iNOS expression and NO
production. These results are consistent with previous reports
showing that CD36 mediates free radical production in many
neuroinflammatory conditions including Alzheimer disease and
cerebral ischemia [11,33,34], and support a key role of CD36 in
Figure 7. Western blot analysis of p-Fyn. BV2 microglia were
treated or not with neurotoxic prion peptides (100 mM) for 24 h after
1 h-preincubation with anti-CD36 mAb. The role of Fyn in CD36
signaling was examined by assessing Fyn phosphorylation. A. Extracts
were prepared and immunoblotted with phospho-Fyn (p-Fyn) antibody
as described in Materials and Methods. The blot was stripped and
reprobed with anti-b-actin antibody to estimate the total amount of
protein loaded in gel. Representative blots of p-Fyn and b-actin are
shown. B. Bars represent the relative levels of cleaved p-Fyn, compared
with b-actin, and were expressed as arbitrary units. Data are the
means6S.D of three independent experiments. * P,0.05, significantly
different from control cells.
doi:10.1371/journal.pone.0030756.g007
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Several lines of evidence indicate that NF-kB activation is
crtitical for the induction of iNOS and the upregulation of
inflammatory cytokines such as IL-1b and IL-6 [35,36,37,38].
Moreover, the activation of NF-kB in macrophages and microglia
exposed to neurotoxic prion peptides is well documented
[30,39,40]. NF-kB activation was also linked to CD36 signaling
[41,42]. We therefore examined the effect of CD36 blocking on
PrP106–126-induced NF-kB activation. The observed results
showed nuclear translocation of p65 in PrP106–126-treated cells
even in the case of anti-CD36 monoclonal antibody pretreatment.
This finding may account for why the release of TNF-a in the
treated cells was not affected by CD36 blockade. However,
keeping in mind that a wide variety of signals emanating from
antigen receptors, pattern-recognition receptors, receptors for the
members of TNF and IL-1 cytokine families, and others induce
differential activation of NF-kB, this result is not conclusive and
does not rule out the possibilty that CD36 blockade may inhibit
microglial activation by interfering with NF-kB activation. We can
speculate, for example, that PrP106–126 leads to the activation of
NF-kB through several pathways and that, if any, only one or
some of these pathways are CD36-mediated.
We also examined the effect PrP106–126 treatment on caspase-1
activation. The result showed that PrP106–126 stimulated capase-1
cleavage and that CD36 blockade did not interfere with this
activation although a slight reduction of caspase-1 cleavage was
observed after a moderate PrP106–126 treatment. This suggests that
CD36 may not play a central role in PrP106–126-induced capase-1
activation. Caspase-1 is an inflammatory caspase, whose main
substrates are cytokines that are crucial to the inflammatory
response such IL-1b and IL-18. Caspase-1 is present as an inactive
proform in the cytoplasm and it is activated by proteolytic self-
processing. Several multimolecular proteins complexes, referred to
as inflammasomes, have been identified as caspase-1 activators
[43,44,45]. To our knowledge, this is the first time an association
between neurotoxic prion peptides and activation of caspase-1 in
microglia is reported. This finding suggests that inflammsome
activation may be involved in neurotoxic prion peptides-induced
inflammation and, if confirmed by further studies, would add
prion diseases to a long list of diseases and inflammatory
conditions that have been associated with inflammasome.
Caspase-1 activation leads to post-translational processing and
release of the mature, biologically active forms of IL-1b and IL-18,
which are potent mediators of inflammation, being responsible for
a variety of effects associated with host responses to microbial
invasion and tissue damage [43]. As mentioned above, PrP106–126
induced IL-1b upregulation and capase-1 activation. However,
CD36 blockade resulted only in the inhibition of PrP106–126-
induced upregulation of IL-1b without a significant effect on
capase-1 activation, which suggests that CD36 mediates PrP106–
126-induced upregulation of IL-1b through a capase-1-indepen-
dent pathway. Accordingly, the fact that CD36 blockade
significantly downregulated mRNA expression of IL-1b in
PrP106–126-treated cells supports a direct involvement of CD36-
mediated signaling at the level of mRNA transcription of IL-1b in
microglia exposed to neurotoxic prion peptides.
Finally, we examined the effect of PrP106–126 treatment on Fyn
phosphorylation. Fyn is a membrane associated non-receptor
protein tyrosine kinase that belongs to the Src family of
cytoplasmic tyrosine kinase [46]. Fyn is expressed predominately
in tissues of neuronal and hematopoietic origin and has been
shown to be involved in CD36-mediated signaling [47]. The
decrease in p-Fyn level observed after CD36 blockade in PrP106–
126 treated microglia suggests that the participation of CD36 in the
interaction between PrP106–126 and microglia may be mediated by
Src tyrosine kinases. This is supported by preliminary results from
a research work in our lab on CD36 signaling during PrP106–126-
induced micrglial activation, which is currently underway, and
which showed that Src tyrosine kinase inhibitor, PP2, can
significantly downregulate PrP106–126-induced i-NOS upregulation
in BV2 micrglia.
In conclusion, we have shown that CD36 is involved in PrP106–
126-induced microglial activation and that neurotoxic prion
peptides can induce caspase-1 activation in microglia. These
findings unveil a previously unrecognized role of CD36 as a
surface molecule involved in neurotoxic prion peptides-microglia
interactions and raise the possibility of inflammasome involvement
in the pathogenesis of prion diseases, thus providing new insights
into the mechanisms underlying the activation of microglia by
neurotoxic prion peptides. Although more studies are needed to
confirm and explore these initial findings, our study identified a
potential molecular target for the treatment of prion diseases and
provides perspectives for new therapeutic strategies for prion
diseases by modulation of CD36 signaling.
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